ストックスクリーナーアプリを入手
9.16
1.51%
-0.14
前日終値:
$9.30
開ける：
$9.43
24時間の取引高:
8.80M
Relative Volume:
4.70
時価総額：
$1.54B
収益：
$68.56M
当期純損益:
$-437.99M
株価収益率:
-2.8952
EPS:
-3.1639
ネットキャッシュフロー:
$-396.61M
1週間 パフォーマンス:
+7.51%
1か月 パフォーマンス:
+4.45%
6か月 パフォーマンス:
+54.47%
1年 パフォーマンス:
+75.82%
1日の値動き範囲:
$9.01
$9.81
1週間の範囲:
$8.49
$9.81
52週間の値動き範囲:
$4.155
$11.66
Vir Biotechnology Inc Stock (VIR) Company Profile
名前
Vir Biotechnology Inc
セクター
電話
415-906-4324
住所
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
9.16 | 1.54B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | 開始されました | Evercore ISI | Outperform |
| 2025-08-27 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-09-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-03-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-02-21 | アップグレード | Goldman | Neutral → Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | 開始されました | SVB Leerink | Outperform |
| 2022-09-09 | 開始されました | Morgan Stanley | Underweight |
| 2022-03-03 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-01-27 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-09-14 | アップグレード | Goldman | Neutral → Buy |
| 2020-09-11 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-08-20 | 開始されました | Needham | Buy |
| 2020-03-19 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-03-13 | ダウングレード | Goldman | Buy → Neutral |
| 2020-02-27 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-14 | 開始されました | Robert W. Baird | Neutral |
| 2019-11-05 | 開始されました | Barclays | Overweight |
| 2019-11-05 | 開始されました | Cowen | Outperform |
| 2019-11-05 | 開始されました | Goldman | Buy |
| 2019-11-05 | 開始されました | JP Morgan | Overweight |
すべてを表示
Vir Biotechnology Inc (VIR) 最新ニュース
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
Vir Biotechnology Inc (VIR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vir Biotechnology Inc (VIR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vir Biotechnology Inc (VIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vir Biotechnology Inc (VIR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership - Stocktwits
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million - AOL.com
VIR Should I Buy - Intellectia AI
VIR Maintained by Morgan Stanley -- Price Target Raised to $27 - GuruFocus
Morgan Stanley Raises Vir Biotechnology (NASDAQ:VIR) Price Target to $27.00 - MarketBeat
Vir Biotechnology, Inc. Stock 12‑Month Price Target Raised to $21.56, Implies 161% Upside - TradingView
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors - BioSpace
Vir Biotechnology (VIR) director awarded RSUs and stock options in new grants - Stock Titan
Vir Biotechnology (VIR) director Coughlin reports zero share ownership - Stock Titan
Vir Biotechnology Adds Timothy Coughlin to Board, Audit Chair - TipRanks
Vir Biotechnology appoints Timothy Coughlin to board - Investing.com UK
Vir Biotechnology appoints Timothy Coughlin to board By Investing.com - Investing.com South Africa
Vir Biotechnology (VIR) appoints Timothy Coughlin as director and Audit Committee chair - Stock Titan
WINTON GROUP Ltd Buys 131,555 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology: Analyzing the Bullish Thesis on VIR-5500 and mCRPC OpportunityAnalyst Coverage Count - newsline.com
VIR News | VIR BIOTECHNOLOGY INC (NASDAQ:VIR) - ChartMill
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now? - Insider Monkey
Earnings call transcript: Vir Biotech reports larger-than-expected Q1 2026 loss - Investing.com
Vir Biotech Q1 2026 presentation: $2.2B partnerships fuel oncology pivot - Investing.com
VIR Maintained by Leerink Partners -- Price Target Raised to $21 - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $21.00 - MarketBeat
Insider Sell: Brent Sabatini Sells Shares of Vir Biotechnology I - GuruFocus
Insider Sell: Janet Napolitano Sells 3,200 Shares of Vir Biotech - GuruFocus
Vir Biotechnology director Janet Napolitano sells $30,239 in stock - Investing.com UK
Vir Biotechnology director Janet Napolitano sells $30,239 in stock By Investing.com - Investing.com India
Vir Biotechnology (VIR) director Napolitano sells 3,200 shares under 10b5-1 plan - Stock Titan
Vir Biotechnology (VIR) SVP sells 379 shares in pre-planned trade - Stock Titan
VIR (NASDAQ: VIR) Form 144 lists 379 ESPP shares; insider sold 7,711 - Stock Titan
[144] Vir Biotechnology, Inc. SEC Filing - Stock Titan
Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Vir Biotechnology, Inc. (VIR) Presents at EASL Congress 2026Slideshow (NASDAQ:VIR) 2026-05-30 - Seeking Alpha
Vir Biotechnology (VIR) director receives RSU and stock option grants - Stock Titan
Vir Biotechnology (VIR) director granted 8,000 RSUs and 16,000 options - Stock Titan
Vir Biotechnology (VIR) director granted RSUs and 16,000-share stock option - Stock Titan
Vir Biotechnology (VIR) director receives 8,000 RSUs and 16,000 stock options - Stock Titan
Vir Biotechnology (VIR) director awarded 8,000 RSUs and 16,000-share stock option - Stock Titan
Vir Biotechnology (VIR) director granted RSUs and 16,000-share option - Stock Titan
Vir Biotechnology Inc (VIR) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):